BML, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,908 JPY | 0.00% |
|
-0.14% | -3.07% |
| Sales 2024 * | 138B 893M 74.43B | Sales 2025 * | 141B 913M 76.16B | Capitalization | 113B 734M 61.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.37B 41.25M 3.44B | Net income 2025 * | 6.67B 43.2M 3.6B | EV / Sales 2024 * | 0.26 x |
| Net cash position 2024 * | 78.11B 506M 42.2B | Net cash position 2025 * | 72.37B 469M 39.1B | EV / Sales 2025 * | 0.29 x |
| P/E ratio 2024 * |
17.7
x | P/E ratio 2025 * |
16.8
x | Employees | 4,415 |
| Yield 2024 * |
2.75% | Yield 2025 * |
2.87% | Free-Float | 56.19% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -0.14% | ||
| Current month | -0.03% | ||
| 1 month | -1.46% | ||
| 3 months | +2.00% | ||
| 6 months | +2.83% | ||
| Current year | -3.07% |
1 week
2 867.00
2 940.00
1 month
2 867.003 125.00
Current year
2 613.003 125.00
1 year
2 594.003 250.00
3 years
2 594.004 985.00
5 years
2 307.004 985.00
10 years
1 360.504 985.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kensuke Kondo
PSD | President | 57 | 01/94/01 |
Yuji Yamashita
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/88/01 |
Nobuki Arai
ADM | Chief Administrative Officer | 64 | 01/05/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kensuke Kondo
PSD | President | 57 | 01/94/01 |
Nobuki Arai
ADM | Chief Administrative Officer | 64 | 01/05/01 |
Tatsuharu Arai
BRD | Director/Board Member | 67 | 01/21/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 23 M€ | +1.99% | - | |
| 0.10% | 19 M€ | +3.93% | ||
| 0.02% | 73 M€ | +18.87% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 2,908 | 0.00% | 33 100 |
| 01/24/01 | 2,908 | -0.51% | 35,700 |
| 30/24/30 | 2,923 | +1.04% | 40,800 |
| 26/24/26 | 2,893 | +0.56% | 47,600 |
| 25/24/25 | 2,877 | -1.07% | 32,200 |
Delayed Quote Japan Exchange, May 02, 2024 at 11:30 am IST
More quotes
BML, INC. is mainly engaged in the clinical testing as well as related business. The Testing segment engages in the commissioned work of clinical testing. The Medical Information Systems segment is engaged in the manufacturing and sales of system equipment for medical institutions, as well as provision of medical information service.
Calendar
10/05/2024
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
2,908
JPY
Average target price
3,033
JPY
Spread / Average Target
+4.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.07% | 719M | |
| -19.14% | 8.22B | |
| +47.02% | 3.73B | |
| -7.71% | 2.46B | |
| -38.71% | 2.46B | |
| -8.84% | 2.36B | |
| -13.84% | 1.78B | |
| -19.01% | 1.52B | |
| -40.78% | 1.21B | |
| +8.32% | 1.12B |
- Stock Market
- Equities
- 4694 Stock
